Home › GLP-1 Medications › Novo Nordisk › Ozempic
Latest three-month snapshot through 2026-08-05 · 1 wave. Use the controls above to change the window.
GLP-1 Medications · 1 wave · n=72 answers, pooled
How often each model brings the brand up in recommendation answers.
| model | share of voice | answers |
|---|---|---|
| ChatGPT | 79% | 19 of 24 |
| Claude | 96% | 23 of 24 |
| Gemini | 50% | 12 of 24 |
Wave-by-wave share of recommendation answers that named this brand.
| wave | share of voice | answers | change |
|---|---|---|---|
| 2026-08-05 | 75% | 54 of 72 |
Recurring descriptions in the models' own words, grouped by theme.
“Additionally, weekly injections are more convenient than Victoza's daily regimen, and both manufacturers offer copay saving cards that can dramatically lower your out-of-pocket costs.”
“Choose **Ozempic** if your primary goal is managing Type 2 Diabetes or protecting your heart If you have Type 2 diabetes, **Ozempic** is the correct choice.”
“If Your Goal is Managing Type 2 Diabetes: Choose **Ozempic**”
“However, Rybelsus was also approved for cardiovascular risk reduction in adults with type 2 diabetes.”
“* **The Ozempic Routine:** Ozempic is a once-weekly injection.”
“Mounjaro is a first-of-its-kind **dual GIP and GLP-1 receptor agonist**.”
“* **Ozempic** is specifically FDA-approved to lower blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events (like stroke or heart attack) in diabetics with established heart disease.”
“your insurance might not cover Victoza, but it might cover **Ozempic (semaglutide)** or **Trulicity (dulaglutide)** with a much lower monthly copay.”
“Both are semaglutide GLP-1 medicines, and both carry similar core risks.”
“Ozempic contains the same active ingredient (semaglutide) but is primarily approved for **type 2 diabetes** and related cardiovascular/kidney-risk indications.”
237 exact quoted mentions in this snapshot, grouped by coded tone. Recent quotes are deduplicated and mixed across models.
“**Ozempic:** For cash-paying patients, NovoCare offers the first two months at **$19”
“Ozempic is FDA-approved for type 2 diabetes and is the same molecule as Wegovy but at a lower maximum dose, and is widely prescribed off-label for weight loss; if you have type 2 diabetes, your doctor may have more flexibility getting Ozemp”
“results tend to be more modest than Ozempic/Wegovy injections or the newly approved oral Wegovy pill”
“FDA-approved to improve glucose and reduce risks of kidney-function decline, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD.”
“**Ozempic (semaglutide injection)** — FDA-labeled to reduce certain cardiovascular risks in people with T2D and known heart disease, and to reduce kidney-disease worsening/kidney failure and cardiovascular death in adults with T2D and CKD.”
“Slightly less weight loss on average, but a longer safety track record. Semaglutide and liraglutide have the most extensive long-term safety data with over 7 years of clinical use, while newer medications like tirzepatide continue accumulat”
“you might consider alternatives like **Ozempic (semaglutide)** or **Trulicity (dulaglutide)**. * **Why they might be cheaper:** While these medications do not have generic versions yet and have high cash retail prices, **insurance formulari”
“**Semaglutide** – available as injectable (Ozempic) or oral (Rybelsus)”
“Ozempic (semaglutide) can be very worthwhile when you have **type 2 diabetes**, especially if weight, heart disease, or chronic kidney disease are also concerns. It improves blood sugar and, in the FDA-approved diabetes population, reduces ”
“Ozempic (semaglutide) is highly effective for managing Type 2 diabetes and supporting weight loss, but its high list price (often between $900 and $1,300 per month out-of-pocket) makes it inaccessible for many.”
“Avoid compounded "semaglutide" or "tirzepatide," research peptides, and products claiming to be generic Ozempic/Wegovy/Mounjaro/Zepbound.”
“Novo Nordisk (maker of Ozempic and Wegovy) has been hit with **multiple FDA warning letters in 2026** for misleading TV ads.”
“Buying Ozempic or Mounjaro solely [for weight loss is not recommended, implied by the warning section]”
“Head-to-head data and real-world studies show that tirzepatide is significantly more effective for weight loss than semaglutide (the active ingredient in Ozempic and Wegovy), which typically results in about 15% weight loss.”
“Brand-name weekly GLP-1s (like Ozempic, Wegovy, or Mounjaro) do not have generic options yet and routinely cost upwards of $900 to $1,000+ per month without insurance.”
Which competitors models suggest when shoppers ask for something cheaper.
35 of 237 mentions appear alongside an identifiable web citation. Citation does not establish causation.
| cited source | mentions |
|---|---|
| eden.health | 3 |
| buzzrx.com | 3 |
| primetherapeutics.com | 2 |
| noom.com | 2 |
| plexusdx.com | 2 |
| healthline.com | 2 |
| drugwatch.com | 2 |
| singlecare.com | 2 |
| prescriberpoint.com | 1 |
| cochrane.org | 1 |
| everydayhealth.com | 1 |
| fda.gov | 1 |
Stores and sites models name as places to buy this brand.
| retailer | mentions |
|---|---|
| NovoCare | 3 |
| GoodRx | 2 |
| Publix | 1 |
| Publix Pharmacy | 1 |
| NovoCare Pharmacy | 1 |
Method: fixed shopper questions asked repeatedly to Claude, OpenAI GPT and Gemini with web search on. Shares are the percentage of recommendation answers mentioning the brand. Quotes are AI outputs; full transcripts are kept as receipts.